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ENDOGENOUS B E T A - A D R E N E R G I C R E C E P T O R 
ANTAGONISTS (EBARA) IN H E A L T H AND DISEASE 
N. Temnyalov 
Department of Pharmacology, Medical University of Varna, Varna 
Data accumulated in investigations under in vivo and in vitro conditions con­
firm author's concept about the existence of EBARA, certain endogenous biologically 
active substances in a healthy and pathologically altered organism when no beta-
adrenergic blockers of synthetic, semi-synthetic, and natural origin have been intro­
duced. Based on the suggested model about the interrelation between the endogenous 
specific beta-adrenergic receptor antagonists (ESBARA) and the endogenous non­
specific beta-adrenergic receptor antagonists (ENBARA) it has been accepted that 
"three of four agonist-activated G-protein-coupled beta-adrenoreceptors" are under 
the antagonistic control of beta-arrestins (specific co-factors of 6 izoenzyme beta-
adrenoreceptor kinases) through their phosphorylation (Lefkowitz group) while the 
fourth beta-adrenoreceptor is, probably, antagonized by urea, manganese ions, hy­
drogen peroxide, L-taurine, etc. The efforts of the groups of Lohse and Di Blasi dem­
onstrated a superexpression of beta-arrestins in patients with heart failure when no 
other reason was present at all. Data about ENBARA indicate their involvement in 
patients with chronic renal failure on periodic haemodialysis and with cystic kidney 
fibrosis as well. 
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Until recently, the problem of en­
dogenous beta-adrenergic receptor an­
tagonists ( E B A R A ) has not been dis­
cussed in the biomedical and clinical lit­
erature (10-12). Based on own results 
obtained under in vivo and in vitro condi­
tions, our group describes "urea as endog­
enous metabolic factor with behaviour of 
a non-selective beta-adrenergic receptor 
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blocking agent" (8). It is to be underlined 
that using scattered literature data we de­
velop a concept of endogenous non-spe­
cific beta-adrenergic receptor antagonists 
(ENBARA) and of endogenous specific 
beta-adrenergic receptor antagonists 
(ESBARA) (10-12). Further developing 
our concept of E N B A R A and E S B A R A 
we accept that under physiological condi­
tions both E B ARAs act as endocoids (au-
tacoids), i . е., our drugs of organism in 
agreement with Lai et al. (1984, cited af­
ter 11). It is possible that in early disor­
ders of homeostasis and under pathophysi-
s 
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ologic conditions both E B ARAs are en­
larged, too (1,9,11,13). 
Data under in vivo conditions sup-
porting the concept of ENBARA originate 
from experiments carried out on 
anaeshetized cats and dogs (11) and rats 
(7). Results show that: 1) isoproterenol 
(+)-chronotropic and vasodepressor ef­
fects ranging 1 -2-4 nmol i. v., prior to and 
at 1 s t , 2 n d , 3 r d , 4 t h and 5 t h h after single 
injection of urea 17 nmol/kg i . v. are dose-
and time-dependently antagonized to sig­
nificant degree and 2) after repeated infu­
sions of isoproterenol the vasodepressor 
responses were completely inhibited but 
the positive chronotropic effects were par­
tially inhibited after manganese infusion (1 
mg/kg/min MnCh). However, Strubelt's 
team concluded that "manganese is not a 
beta-blocking substance. If this were so, 
calorigenic and positive chronotopic ac­
tion would be equally inhibited" (8). Ger­
man pharmacologists believed that the prin­
cipal criterion was the adequacy between 
cardiovascular and metabolic effects of 
beta-adrenoblockers and manganese ions 
in parallel. 
Data under in vitro conditions sup-
porting the concept of E N B A R A also 
originate from several groups of investi­
gators. We could demonstrate a non-spe­
cific, non-selective, and non-competitive 
antagonism of isoproterenol and fenoterol 
relaxation in arterial and venous prepara­
tions at isotonic and isometric regimens 
(12). Urea 10-100 mM decreased nora­
drenaline contractile effects and mechani­
cal activity of guinea-pig isolated heart - a 
beta-l,2-adrenergic response (Kersing 
and Brass, 1976, cited after 11). Similar 
data about manganese ions were obtained 
showing positive inotropic effect of 
adrenaline in guinea-pig atria (Meinertz and 
Scholz, 1969, cited after 11). The antago­
nistic effects of hydrogen peroxide on 
beta-adrenoceptors such as inhibition of 
adenylyl cyclase activity and с AMP con­
tent in calf heart membrane preparations 
were described (2). The antagonistic ef­
fect of L-taurine on isoproterenol 
inotropism of chick heart was reported (5). 
Data under clinical conditions sup-
porting the concept of ENBARA originate 
from our clinico-pharmacological ap­
proach as a logic continuation of experi­
mental pharmacological data with urea as 
ENBARA. We studied haemodialyzed 
and healthy males. Using a time-plateau 
concentration principle we performed an 
isoproterenol infusion of 12-24-48-96 
pmol/kg/min immediately before and after 
the end of 4 t h hour of regular haemodialysis 
procedure. In contrast to the control age-
matched group we observed an absent 
dose-response curves fashion of isoprot­
erenol (+)-chronotropic and vasodepres­
sor effects before the haemodialysis pro­
cedure. Removal of urea by 55 % at the 
end of the same procedure was the major 
factor for significantly restored isoproter­
enol (H-)-chronotropic effect (9). De­
creased cardiac beta-adrenoceptor re­
sponsiveness was reported in patients with 
cystic fibrosis (Motulsky and Insel, 1982, 
cited after 11) and attributed to chronic 
renal failure. 
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Data under in vitro conditions sup-
tfting the concept of ESBARA_ap-
peared since 1990 up to now. Lefkowitz's 
group isolated beta-arrestin, a 418-
aminoacid protein homologous to the reti­
nal arrestin regulating beta-adrenergic re­
ceptor function of 75 % agonist-activated 
beta-adrenoceptors (4). Beta-arrestin-2, 
Ijovel member of the arrestin-beta-
restin-gene family exhibited 78 % 
aminoacid density with beta-arrestin-1. 
They acted as specific co-factors of beta-
adrenergic-receptor kinases 1 and 2. Both 
beta-arrestins were equipotent and pre­
dominantly localized in neuronal tissues 
exerting homologous desensitization of 
beta-adrenergic receptors. 
Data under clinical conditions sup-
porting the concept of E S B A R A started 





1 - beta-arrestin 1 
2 - beta-arrestin 2 
3 - arrestin 3 
1, 2, 3 - co-factors of 6 BARK 
(6-Adrenergic Receptor Kinases) 
6-ADRENERGIC RECEPTOR -
MEDIATED ENDOCYTOSIS -
INDUCED DOWN REGULATION 
(Schematically presented by la, 2a, 3a) 





A - carbamide (urea) 
В - manganese ions 
(MnCl2) 
С - hydrogen peroxide 
D - 1-taurine 
Fig. 1. Schematic presentation of ESBARA 
and ENBARA modelling in vertebrates 
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United efforts of German pharmacologists 
and clinicians revealed an expression of 
beta-arrestin and beta-adrenergic recep­
tor kinases in the failing human heart (13). 
Benovic's group found out an increase in 
beta-adrenergic receptor kinase 1 protein 
expression from younger hypertensive 
patients (1). 
This enzyme activity increase 
probably underlies the reduced beta-adr­
energic receptor responsiveness typical of 
the hypertensive state (11,13). 
In conclusion a lot of data, own 
and from the recent literature available, un­
doubtedly support the role of E B A R A 
under physiological and pathological con­
ditions in animals and humans. Schemati­
cally, our model was presented in Fig. 1 
reflecting ENBARA and ESBARA inter­
relationships. 
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Ендогенните бета-адренергични рецепторни блокери (ЕБАРА) 
при здраве и при болест 
Н. Темня лов 
Катедра по фармакология, Медицински университет-Варна 
Резюме: Натрупаните до сега данни за изследвания в условия in vivo и in vitro 
поддържат развиваната от автора концепция за ЕБАРА - определени ендогенни 
биологично активни вещества в здравия и в болния организъм, когато не са въвеждани 
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ета-адренергични блокери от синтетичен, полусинтетичен или природен произход. 
а базата на предложения модел за съотношението на ендогенните специфични бета-
-ренергични рецепторни блокери (ЕСБАРА) и ендогенните неспецифични бета-
ренергични рецепторни блокери (ЕНБАРА) се приема, че "три от четири агонист-
ктивирани G-протеин-куплирани бета-адренорецептори" са под антагонистичния 
онтрол на бета-арестини (специфични ко-фактори на 6 изоензима бета-
-ренорецепторни кинази) чрез тяхното фосфорилиране (групата на Lefkowitz), а 
етвъртият бета-адренорецептор вероятно се антагонизира от урея, манганови йони, 
одореден прекис, L-таурин и др. Усилията на групите на Lohse и Di Blasi показаха 
уперекспресия на бета-арестини при болни със сърдечна недостатъчност, без да 
ма друга причина. Данните за ЕНБАРА сочат участието им при болни с хронична 
ъбречна недостатъчност на периодична хемодиализа и с цистична фиброза на 
ъбреците. 
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